FeesSafety
Pluang+

Golar LNG releases 2025 ESG report highlighting operational growth and low carbon intensity.

Others
23 Oct 2026
GlobeNewsWire
View Source
Bullish
Golar LNG releases 2025 ESG report highlighting operational growth and low carbon intensity.

Golar LNG published its 2025 Environmental, Social and Governance (ESG) report, showcasing growth in its floating LNG fleet and increased production. The report highlights record-low retainage on the Gimi FLNG and strong operational performance from the Hilli FLNG. Both units exceeded their low carbon-intensity targets, reflecting improved efficiency. The report covers key areas including health, safety, environmental impact, community engagement, innovation, and governance, signaling Golar's commitment to sustainable operations.

Golar LNG's 2025 Environmental, Social and Governance report is the subject here. For readers following the Energy sector, here is Pluang's market snapshot as of Oct 23, 2026 18:01 WIB: out of 79 priced US Energy stocks, 53 rose and 19 fell. Notable movers include WMB at USD 72.15 with a 1-day change of +2.15%, EQNR at USD 47.39 with +2.09%, and SU at USD 79.00 with +2.05%.

More News

Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital has closed its fifth Collateralized Loan Obligation (CLO) offering, raising $403.6 million. This deal brings the firm's total CLO issuance to more than $2 billion across five deals in less than two years, demonstrating strong investor co...

Company Fundamentals
Bullish
57 minutes ago
Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

ImPact Biotech reported positive early results from its Phase 1 trial of Padeliporfin VTP in patients with locally advanced, unresectable pancreatic cancer. Of 12 patients treated, 75% have undergone or are scheduled for surgery, with over half achie...

Company Fundamentals
Bullish
57 minutes ago
Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta Therapeutics presented positive preclinical and early clinical data for AVA6103, a novel peptide-drug conjugate targeting FAP-positive tumors resistant to Enhertu. AVA6103 demonstrated superior tumor control and prolonged drug release in precl...

Market News
Bullish
57 minutes ago
eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware Associates has introduced a free five-minute AI readiness assessment to help regulated organizations identify and prioritize security risks related to sensitive file access in Microsoft 365 before deploying Copilot. The assessment highlight...

Others
Neutral
1 hour ago
Balchem posts Q3 2026 sales of $290.7M, net earnings up 16%, driven by growth in all segments.

Balchem posts Q3 2026 sales of $290.7M, net earnings up 16%, driven by growth in all segments.

Balchem Corporation reported strong Q3 2026 results with net sales of $290.7 million, up 8.6% year-over-year, and net earnings of $46.7 million, a 16% increase. Growth was driven by all three segments: Human Nutrition and Health, Animal Nutrition and...

Company Fundamentals
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App